Oridonin, a promising ent-kaurane diterpenoid lead compound

76Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Oridonin belongs to ent-kaurane tetracyclic diterpenoid and was first isolated from Isodon species. It exhibits inhibitory activities against a variety of tumor cells, and pharmacological study shows that oridonin could inhibit cell proliferation, DNA, RNA and protein synthesis of cancer cells, induce apoptosis and exhibit an antimutagenic effect. In addition, the large amount of the commercially-available supply is also very important for the natural lead oridonin. Moreover, the good stability, suitable molecular weight and drug-like property guarantee its further generation of a natural-like compound library. Oridonin has become the hot molecule in recent years, and from the year 2010, more than 200 publications can be found. In this review, we summarize the synthetic medicinal chemistry work of oridonin from the first publication 40 years ago and share our research experience of oridonin for about 10 years, which may provide useful information to those who are interested in this research field.

Cite

CITATION STYLE

APA

Li, D., Han, T., Liao, J., Hu, X., Xu, S., Tian, K., … Xu, J. (2016, September 1). Oridonin, a promising ent-kaurane diterpenoid lead compound. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms17091395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free